Full Breakdown
Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42 %
By Drooid · · How we work
Trial Results and Core Findings
In a late-stage Phase 3 study (INTerpath-001) of 1,137 adults with high-risk cutaneous melanoma, the experimental mRNA vaccine intismeran combined with Merck’s checkpoint inhibitor Keytruda lowered the relative risk of disease recurrence or death by 42 % versus Keytruda alone. The combination also reduced the risk of distant metastasis or death by 38 %. After a median follow-up of about two years, 82.2 % of patients receiving the vaccine remained free of melanoma, compared with 70 % in the control arm. The protocol administered nine intramuscular doses roughly every three weeks, beginning about 13 weeks after tumor resection.
Background & Context
Melanoma accounts for roughly 8,000 deaths annually in the United States. Standard adjuvant therapy after surgery relies on immune-checkpoint inhibitors such as Keytruda, which release a molecular “brake” on T-cells. Earlier Phase 2 data suggested that pairing a personalized vaccine with checkpoint blockade could improve outcomes, but no mRNA-based cancer vaccine had previously shown efficacy in a pivotal trial. Intismeran encodes up to 34 tumor-specific neoantigens identified by sequencing each patient’s resected tumor, training the immune system to recognize residual cancer cells.
Data & Statistics
| Metric | Vaccine + Keytruda | Keytruda alone |
|---|---|---|
| Patients enrolled | 1,137 (757 vaccine, 380 placebo) | — |
| Relative risk reduction (recurrence/death) | 42 % (HR 0.58) | — |
| Relative risk reduction (distant metastasis/death) | 38 % (HR 0.62) | — |
| Recurrence-free survival at 2 years | 82.2 % | 70.0 % |
| Common adverse events (fever, injection-site pain) | Similar to Keytruda; grade 3-5 events 14.2 % vs 13.4 % | — |
| Treatment discontinuation due to adverse events | 7 % | 5 % |
Official Statements & Responses
Trial investigator Dr. Hussein Tawbi called the findings “highly statistically significant” and unlikely to be due to chance. The companies said they are engaging with U.S. regulators and aim for a possible launch in 2027.
Verbatim Quotes
- “With this ability to create new T cells that are specific to your tumor... the clinical impact is very profound, and as we saw in the Phase 2 (trial), very lasting,” — Stephane Bancel, Moderna CEO
- “It will be seen as the first step toward using cancer vaccines to their full potential,” — Dr. Robert Vonderheide
- “While approval seems likely, commercial success is far less certain,” — Trung Huynh, RBC analyst
Timeline
- October 22, 2026 – Moderna and Merck disclosed the Phase 3 results, reporting the 42 % risk reduction.
- October 24 – Detailed data were slated for presentation at the European Society for Medical Oncology (ESMO) congress in Madrid.
- August 18 – Moderna’s share price rose sharply after the earlier announcement of trial success.
- October 21 – The stock rally peaked, with a 290 % gain since August 18.
What’s Next
The companies are preparing regulatory filings in the United States and Europe, targeting a possible 2027 launch pending approval. Ongoing INTerpath studies are evaluating intismeran with Keytruda in renal cell carcinoma, non-small-cell lung cancer, bladder cancer, and additional melanoma cohorts. Longer-term overall-survival data remain immature, and further follow-up will determine whether the early recurrence-free benefit translates into a survival advantage.